CASPR is funding a VA study on GLP-1s and opioid use in veterans

Our first collaboration with the Department of Veterans Affairs.

I’m pleased to announce that CASPR is funding a study at the Department of Veterans Affairs (VA) on the impact of GLP-1s on opioid use disorder (OUD) in veterans.  

This will be a retrospective patient health record study, examining diabetes and obesity patients who received a GLP-1 and their subsequent rates of opioid overdose and other health outcomes. We are collaborating with Dr. Dave Oslin, CHERP Core Investigator, who will run the study with others at the VA.

The VA has stable, long-term relationships with their patients, which can be particularly helpful in studying opioid use disorder outcomes. We hope this study will contribute to the growing clinical trial and retrospective study literature on GLP-1s and addiction and could be the first of several collaborations between CASPR and the VA.

The goal of our research program is to advance high-impact studies and clinical trials to advance the development and adoption of breakthrough medications for addiction. A deep thank you to CASPR’s donors and funders who have made this study possible.